A new drug developed by scientists at the Florey Institute of Neuroscience, and the School of Chemistry and Bio21 Institute at the University of Melbourne has dramatically improved clinical and cognitive symptoms of motor neurone disease, also called amyotrophic lateral sclerosis.
Motor neurone disease is a progressive, fatal neurodegenerative disease. Its key hallmark is the death of the brain cells that control muscle movements. This results in muscle weakness and eventually paralysis.
Patients usually die of respiratory failure within three years of diagnosis, and there are no treatments or disease-modifying therapies available.
In this dose-finding trial involving 32 patients, the group given the highest amount of the CuATSM compound showed improved lung function and cognitive ability, compared to the predicted declines observed in standard-of-care patients.
Further, treated patients showed a much slower overall disease progression as measured by a global disability score.
The clinical trial was led by Professor Dominic Rowe at Macquarie University, and Associate Professor Susan Mathers at Calvary Health Care Bethlehem, and sponsored by Collaborative Medicinal Development Pty Ltd with support from FightMND.
Professor Ashley Bush, Chief Scientific Officer of Collaborative Medicinal Development and director of the Melbourne Dementia Research Centre, said “This is the first human evidence for a disease-modifying drug for motor neurone disease. It is a huge breakthrough, and we look forward to confirming the positive results in a larger study soon.”
Associate Professor Kevin Barnham of the Florey, Associate Professor Anthony White at the Queensland Institute of Medical Research, and Professor Paul Donnelly and Associate Professor Peter Crouch from the University of Melbourne, developed and tested CuATSM over a 15-year period.
After showing its therapeutic potential for motor neurone disease in pre-clinical models, the researchers founded a company and licenced the compound to Collaborative Medicinal Development, to take the drug into human studies.
Professor Donnelly said, “It is gratifying to see such promising results made possible by collaborative fundamental research at the interface between chemistry and biology.”
Learn more: Motor neurone disease breakthrough: Patient trial shows impressive clinical results
The Latest on: Motor neurone disease
[google_news title=”” keyword=”motor neurone disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Motor neurone disease
- Cerevel drug for Parkinson’s disease improved symptom control in trialon April 18, 2024 at 3:30 am
Cerevel Therapeutics, which AbbVie is acquiring, said Thursday its drug tavapadon, taken with the common Parkinson's drug levodopa, showed positive results in controlling motor symptoms.
- Men support Motor Neurone Disease Associationon April 18, 2024 at 1:57 am
Northampton Male Voice Choir (NMVC) continues to work tirelessly in support of great causes and, from its fundraising activities during 2023, the choir has donated £2000 to the Motor Neurone Disease ...
- Christchurch man petitions for motor neurone disease to be notifiable after wife's diagnosison April 18, 2024 at 1:09 am
A Christchurch man is petitioning for motor neurone disease to become a notifiable disease. Paul Barton's wife Ally was diagnosed with the debilitating disease when she was 34. He says making it ...
- I&G to build new Rob Burrow Centre for Motor Neurone Diseaseon April 17, 2024 at 9:41 pm
I&G has been appointed by Leeds Teaching Hospitals NHS Trust to build the new Rob Burrow Centre for Motor Neurone Disease in Leeds.
- Motor Neuron Disease Drug Pipeline Research 2024: Comprehensive Insights About 180+ Companies and 200+ Pipeline Drugson April 16, 2024 at 2:11 am
The "Motor Neuron Disease - Pipeline Insight, 2024" drug pipelines has been added tAndMarkets.com's offering.This "Motor Neuron Disease- Pipeline Insight, 2024" report provides comprehensive insights ...
- 'Game-changer' for motor neurone disease soon available in New Zealandon April 15, 2024 at 12:30 am
Only one patient here currently has access to the treatment.
- Member for Pakenham Emma Vulin reveals she is in the early stages of motor neurone diseaseon April 13, 2024 at 5:00 pm
In short: Victorian Labor MP Emma Vulin has revealed she is in the early stages of motor neurone disease (MND). MND is a progressive, terminal illness that damages the nervous system. Ms Vulin ...
- Victorian MP Emma Vulin reveals motor neurone disease diagnosison April 13, 2024 at 3:51 pm
State Labor MP Emma Vulin has revealed she is in the early stages of motor neurone disease. Vulin, the member for Pakenham, announced her diagnosis in a post on her Facebook page on Sunday afternoon.
- Motor neurone disease destroyed my life – now the drug that gave me hope is being taken awayon April 11, 2024 at 9:18 am
When you have a terminal illness like motor neurone disease (MND) you really need to cling hard onto any hope you can. It’s horrifically cruel, and while the scientist Stephen Hawking lived with a ...
- Motor Neurone disease destroyed my life – now the drug that gave me hope is being taken awayon April 11, 2024 at 9:18 am
According to the Motor Neurone Disease Association (MNDA), a person’s lifetime risk of developing MND is around 1 in 300, and in July 2019 I became one of the six people who are diagnosed with ...
via Bing News